ERBB2 and neoplasm: To maximally align both arms of therapy with tumour biology, biomarkers such as ER/PR status, HER2-low expression, Trop-2 density, and proliferation indices (Ki-67), along with genomic alterations within endocrine resistance pathways, can be employed to direct dosing schedules and guide patient populations.